The Inhibition of Calcium Oxalate Crystal Growth by Chondroitin Sulphates, Heparin, Pentosan Polysulphate and Tamm-Horsfall Glycoprotein
A large number of the urinary constituents have been reported to inhibit calcium oxalate crystal growth and aggregation. Pyrophosphate, for example, is a potent inhibitor of crystal growth1 and glycosaminoglycans potent inhibitors of crystal aggregation2. Regarding urinary macromolecular inhibitors of calcium oxalate crystallization, a number of substances such as glycosaminoglycans2, polypeptides3, polyribonucleotides4 and glycoproteins5 have been claimed to be of importance. There has also been a debate as to whether uromucoid or Tamm-Horsfall glycoprotein is a promoter or an inhibitor of the crystallization process6. The purpose of the present study is to compare the inhibition of calcium oxalate crystal growth by pyrophosphate, polyanionic glycosaminoglycans and Tamm-Horsfall glycoprotein. This comparison has also been extended to include two drugs with a structure similar to pyrophosphate and heparin respectively.
KeywordsCrystallization Heparin Polypeptide Oxalate Pyrophosphate
Unable to display preview. Download preview PDF.
- 1.L. H. Smith, J. L. Meyer and J. T. McCall, in: “Urinary Calculi”, L. Cifuentes Delatte, A. Rapado, and A. Hodgkinson, eds., Karger, Basel (1973).Google Scholar
- 4.E. E. Schrier, K. E. Lee, J. L. Rubin, P. G. Werness, and L. H. Smith, in: “Oxalate in Human Biochemistry and Clinical Pathology”, G. A. Rose, W. G. Robertson, and R. W. E. Watts, eds., Wellcome Foundation, London (1979).Google Scholar
- 9.B. Fellström, B. G. Danielson, S. Ljunghall, and B. Wikström, in: “Urolithiasis and Related Clinical Research”, P. O. Schwüle, L. H. Smith, W. G. Robertson, and W. Vahlensieck, eds., Plenum, New York (1985).Google Scholar
- 11.B. Fellström, B. G. Danielson, F. A. Karlsson, and S. Ljunghall, in: “Urolithiasis and Related Clinical Research”, P. O. Schwille, L. H. Smith, W. G. Robertson, and W. Vahlensieck, eds., Plenum, New York (1985).Google Scholar